• Mashup Score: 2
    DENGVAXIA - 1 year(s) ago

    DENGVAXIA For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 9 through 16 years of age with laboratoryconfirmed previous dengue infection and living in endemic areas.

    Tweet Tweets with this article
    • DENGVAXIA | FDA لقاح حمي الضنك، للاشخاص الذين اصيبوا علي الاقل مرة ويعيشوا في منطقة متوطن بها البعوض والمرض https://t.co/RdcjCn3xph

  • Mashup Score: 0

    Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. “RSV can cause serious disease in infants…

    Tweet Tweets with this article
    • FDA Approves New Drug to Prevent RSV in Babies and Toddlers https://t.co/pjMLrzvT22